• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

EPIX Pharmaceuticals to Present at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress

Posted on: Monday, 30 July 2007, 09:13 CDT

EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that two members of the company's senior management team are scheduled to present and participate in the IBC Life Sciences 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress at the World Trade Center and The Seaport Hotel in Boston.

Chen Schor, CPA, chief business officer of EPIX, is scheduled to present "EPIX Pharmaceuticals: From GPCR Drug Discovery Technology to $1.2 Billion Collaboration with GSK" on Monday, August 6, 2007 at 4:10 p.m. EDT. This presentation will focus on the strategic fit of EPIX's GPCR discovery technology and pipeline that led to the $1.2 billion collaboration between EPIX and GlaxoSmithKline. Later that same day, Mr. Schor is also scheduled to serve as the moderator for a panel discussion among five industry experts, "Trends in Discovery Stage Deals," at 5:00 p.m. EDT. This discussion will examine the competitive landscape in the bio-pharmaceutical arena, key considerations in early stage partnering from the licensee and the licensor perspectives and how these factors reflect on trends in collaboration structures and deal terms.

Additionally, J. Thomas Megerian, M.D., Ph.D., executive director, clinical research of EPIX, is scheduled to present "New Paradigms in Drug Discovery: A Case Study with PRX-03140" on Wednesday, August 8, 2007 at 2:35 p.m. EDT. This presentation will focus on PRX-03140, the company's novel, highly selective, small-molecule agonist of a specific GPCR known as 5-HT4 for the treatment of Alzheimer's disease. Currently in a phase 2a clinical trial as a single agent and in combination with Aricept® in patients with mild Alzheimer's disease, PRX-03140 is one of the GPCR programs included in the worldwide multi-target strategic collaboration between EPIX and GlaxoSmithKline. Data from this trial are expected in late 2007.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a deep pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.

This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q.

Source: Business Wire

More News in this Category